Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of the study is to test the efficacy, safety and tolerability of several doses
of BI 1356 BS (1, 5, or 10 mg taken once daily) compared to placebo given for 12 weeks
together with metformin in patients with type 2 diabetes mellitus who are not at goal with
their HbA1c levels. In addition, there will be an unblinded treatment arm with glimepiride as
add-on therapy to metformin for comparison. The influence of several factors (gender, age,
weight, race, etc.) on the bioavailability and efficacy of BI 1356 BS will also be tested in
this study.